These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 2772003)
1. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers. Sawicki W; Deptulski T; Janicki S Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003 [TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects. Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817 [TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule. Halkin H; Almog S; Friedman E Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513 [TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411 [TBL] [Abstract][Full Text] [Related]
5. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
6. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]. Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation]. Pello JY; Auclert L; Rey E; Joly H; Mialet C; Puechavy C; Georges M; Ruffo M; Olive G Arch Mal Coeur Vaiss; 1992 Apr; 85 Spec No 1():13-6. PubMed ID: 1530422 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations]. Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. Keller-Stanislawski B; Marschner JP; Rietbrock N Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374 [TBL] [Abstract][Full Text] [Related]
10. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Vree TB; Dammers E; Valducci R Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327 [TBL] [Abstract][Full Text] [Related]
11. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. Muck B; Bonn R; Rietbrock N Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720 [TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
13. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
14. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439 [TBL] [Abstract][Full Text] [Related]
15. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657 [TBL] [Abstract][Full Text] [Related]
16. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. Rietbrock N; Knoll J; Merz PG; Menke G Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327 [TBL] [Abstract][Full Text] [Related]
17. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man. Johnson KI; Gladigau V; Schnelle K Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392 [TBL] [Abstract][Full Text] [Related]
19. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. Menke G; Schnellhammer R; Rietbrock N Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)]. Kogi K; Chida S; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]